Bithionol (Bitin) Veterinary Grade API, chemically designated 2,2′-thiobis(4,6-dichlorophenol), CAS 97-18-7, is released as a crystalline active substance for formulation into tablets, injections, capsules, powders, granules, premix, and oral solutions. The molecular formula is C₁₂H₆Cl₄O₂S, with molecular mass 356.05 g mol⁻¹. The product is supplied under a manufacturer-specific grade designation because no single global compendial model covers all veterinary dosage-form routes; routine powder, micronized powder, and injection-quality cuts are distinguished by particle-size distribution, endotoxin burden, and residual solvent profile. Release assay is typically 98.0–101.0% on the dried basis by high-performance liquid chromatography against a qualified reference standard, and the reported melting range is 186–190°C. The substance occurs as a white to off-white crystalline powder. Low aqueous solubility of the non-ionized molecule, two ionizable phenolic hydroxyl groups, and the thioether linkage are the primary factors controlling formulation behavior and chemical stability. These properties separate bithionol from benzimidazole anthelmintics and from salicylanilide alternatives in solvent selection, granulation route, and residue-control requirements.

As a veterinary flukicide, bithionol is indicated primarily for adult Fasciola hepatica and F. gigantica infections in cattle, sheep, and goats; in some regions the label also covers paramphistome infections. The API is incorporated into tablets, capsules, powders, granules, premixes, and oral solutions according to the approved formulation. Because bithionol is generally used as a targeted flukicide rather than a broad-spectrum anthelmintic, it is positioned in rotational programs where adult fluke burdens are confirmed by fecal egg count reduction tests or liver inspection data. The product is not typically combined with other flukicides without a stability and compatibility study; co-formulation with alkaline effervescent systems should be avoided unless the phenolate interaction is explicitly controlled.

Chemical Identity, Solubility, and Thermal Boundaries

For identification purposes, infrared absorption spectrophotometry should be performed against a qualified reference standard, with an HPLC retention-time match under the same analytical conditions. A solubility test in dilute sodium hydroxide solution distinguishes bithionol from neutral formulation excipients: the API forms a water-soluble phenolate, whereas neutral diluents remain insoluble. Bithionol is practically insoluble in water at pH 5–7, soluble in ethanol, and only sparingly soluble in non-polar solvents. This solubility profile necessitates surfactant addition for dissolution testing and restricts the use of purely aqueous granulation fluids unless the pH is deliberately increased to form the phenolate. Loss on drying is performed below the melting range, typically at 105°C using USP <731>, to measure free moisture rather than thermal decomposition. Sulfated ash by USP <281> and residual solvents by USP <467> are included in non-injection release; the injection-quality cut adds endotoxin control by USP <85> and particulate matter by USP <788> where the finished injectable is subject to compendial testing. Elemental impurities are assessed under ICH Q3D; the certificate of analysis should report nickel, palladium, and chromium because these elements can be introduced through hydrogenation catalysts or stainless-steel contact surfaces. The API should be stored in tightly closed, light-resistant containers; the phenolic groups are susceptible to oxidative discoloration under prolonged light and high humidity.

For dosage-form route selection, the API particle-size specification is more important than a single average number. Tablet and capsule work typically uses a micronized cut with a controlled D10, D50, and D90 to improve blend uniformity and dissolution; premix work may use a coarser or densified cut to reduce dust; injection work requires low endotoxin and low particulate cuts. Laser diffraction is the appropriate particle-size method, and the supplier should report the complete distribution rather than an average diameter. If multiple crystalline forms are known, the manufacturer’s reference X-ray powder diffractogram is used as a release fingerprint. Hot-melt extrusion through a twin-screw extruder with L/D 40:1 should be considered only after differential scanning calorimetry and isothermal stress testing confirm that no degradation occurs below the processing temperature; published data for this specific configuration is limited.

What Limits Direct Compression of High-Dose Bithionol Tablets?

For high-dose tablets, direct compression is constrained by the hydrophobic crystalline surface, low bulk density, and poor flowability. The API does not deform plastically under normal tableting pressure and contributes little dry-binding capacity; tablet hardness therefore depends on the dry binder and the precompression dwell time. Production-scale experience on rotary presses with forced feeders shows that content-uniformity drift can occur when the API particle-size distribution is wide or when the API and excipient bulk densities differ substantially. To limit segregation, the API is micronized or milled to a controlled D90, and blending is typically conducted in low-speed tumble blenders with an intensifier bar rather than in high-shear mixers that can generate electrostatic charge and agglomerates. Tablet friability is tested by USP <1216>; disintegration is tested by USP <701>. Dissolution testing requires a surfactant-containing medium because the intrinsic water solubility is too low to maintain sink conditions. The surfactant concentration should be selected from a solubility screen and justified in the analytical validation; an arbitrarily high surfactant level can mask real formulation differences.

Wet granulation with an ethanolic granulating fluid is more robust than direct compression for high-dose tablets. The API is dissolved or suspended in ethanol and massed with lactose monohydrate and povidone; residual ethanol is controlled by USP <467>. Aqueous granulation with sodium hydroxide converts bithionol to the phenolate and may produce a dark, viscous mass with reduced chemical stability; this route is not recommended unless forced degradation data and a buffered endpoint are available. Dry granulation by roller compaction is the preferred solvent-free alternative. Roll compaction pressure and roll speed are adjusted until ribbon density and granule friability meet weight-variability targets; tablets compressed from dry-granulated bithionol may show slightly lower hardness than direct-compressed tablets but usually show improved content uniformity.

For capsule and oral powder dosage forms, the micronized cut is preferred over the coarse crystalline fraction. The API is premixed with a water-soluble carrier and passed through a cone mill to break electrostatic agglomerates before encapsulation or volumetric filling. Because bithionol is practically insoluble in water, dissolution testing of capsules and dispersible powders requires a surfactant or an alkaline medium selected from a solubility screen; the selected medium is then justified in the analytical method validation. Hard gelatin capsules may develop dissolution slowdown if the fill absorbs moisture and the gelatin crosslinks over time; moisture limit and desiccant selection are therefore treated as release parameters for the packaged product. Oral powders intended for feed or drinking water are dry-mixed with dextrose or lactose at the farm or feed mill; the API should be labeled for the specific mixing protocol to ensure uniform distribution because the drug cannot simply be dissolved in water at neutral pH. Oral solutions and drenches are typically non-aqueous or strongly alkaline; if an alkaline drench is used, the phenolate salt should be freshly prepared or stabilized, as oxidative degradation accelerates in alkaline media.

For injectable presentations, non-aqueous vehicles are required because the non-ionized molecule does not reach practical solution concentration in water at physiological pH. Propylene glycol, polyethylene glycol 400, N-methyl-2-pyrrolidone, or combinations are typical screening solvents; the final vehicle must be declared in the marketing authorization, and its batch-to-batch variation must be controlled because changes in viscosity and polarity alter the drug’s solubilization and precipitation on dilution. The API should be pre-dried before dissolution if free moisture exceeds the vehicle specification, as residual water can precipitate the drug and increase degradation during terminal sterilization. Filtration compatibility is evaluated with nylon, polypropylene, and PTFE membranes, because non-aqueous solutions can extract membrane components and cooling after heat sterilization may generate subvisible bithionol crystals. Contact surfaces should be glass-lined or 316L stainless steel; phenolic hydroxyl groups can form colored iron complexes at elevated temperature, and surface passivation should be part of the compounding procedure. Finished injectable sterility is controlled by USP <71>, bacterial endotoxins by USP <85>, and particulate matter by USP <788>; the API supplier normally certifies the injection-grade cut for endotoxin burden and particulate cleanliness, but final sterility is the responsibility of the dosage-form manufacturer. Visible and subvisible particle counts should be checked after thermal cycling and storage at refrigeration because precipitation may occur slowly.

Premix Carryover, Dust Control, and Cross-Contamination Limits

In feed premix operations, carryover control is required because residual bithionol transferred to non-target batches can create tissue residue risks in untreated animals. Dust extraction at dumping stations and milling operations should use cartridge filters, and the organic powder should be assessed for dust deflagration risk because particle-size reduction can increase the fraction of respirable dust. Cleaning validation for mixers, conveyors, and packaging lines should determine the maximum allowable carryover from the daily intake of the most sensitive non-target species, not from visual inspection alone. Because bithionol is poorly water-soluble, dry cleaning followed by an alkaline detergent wash is more effective than water alone; swab sites should include dead zones behind mixer shafts, ribbon tips, and discharge gates. Premix manufacture often uses a carrier such as calcium carbonate, corn cob fraction, or dextrose monohydrate; carrier selection must not interfere with extraction recovery during assay, and the final premix should be checked for uniformity at the beginning, middle, and end of the batch. Granules for sachets and oral powders are dried to a moisture content below the limit set for the packaging material; moisture-proof sachets or foil-lined bags are specified because absorbed moisture can reduce flow and promote particle aggregation.

When comparing bithionol with triclabendazole, the lower molecular mass chlorinated phenolic sulfide is generally described for adult liver fluke infections; published efficacy data for immature fluke stages are less extensive. Unlike benzimidazole anthelmintics such as albendazole and triclabendazole, bithionol does not share the β-tubulin binding mechanism, so cross-resistance cannot be assumed from benzimidazole-resistant fluke populations without in vivo or in vitro confirmation. Salicylanilides including oxyclozanide, closantel, and rafoxanide are commonly highly protein-bound and have prolonged plasma residence; bithionol has a different substitution pattern and lower molecular mass, which changes solvent, formulation, and residue-depletion behavior. In non-aqueous vehicles, bithionol and the salicylanilides may share some processing constraints, but their final injection formulations should not be treated as interchangeable because pH, viscosity, and precipitation on dilution differ. The selection of bithionol over another fasciolicide should be based on target parasite species, stage, local resistance status, dosage-form route, and approved withdrawal period, not on a single chemical class comparison.

Why Rotational Use Requires a Defined Withdrawal Interval

Because withdrawal intervals are product-specific, they must be derived from residue depletion studies conducted under the conditions of the target production system. The residue assay should be validated under regional residue control guidelines, typically using LC-MS/MS with an internal standard and a limit of detection below the established maximum residue limit. If no MRL has been set in a jurisdiction, the producer must follow the local residue control program and may be required to demonstrate depletion below the detection limit before slaughter. Rotational anthelmintic programs cannot transfer withdrawal intervals from closantel, oxyclozanide, or triclabendazole to bithionol; differences in molecular mass, halogen substitution, plasma protein binding, and metabolic pathways produce different tissue-residue profiles. Published residue-depletion data under all production conditions are limited; therefore local studies in the target species are required to support the label interval. The API supplier provides the batch certificate and impurity profile, not the withdrawal interval; that responsibility rests with the marketing authorization holder.